Cambridge, England-based AstraZeneca posted a net loss of $3 million in the three months to June 30, compared with a net profit of $697 million in the same period a year earlier. Revenue slipped... AstraZeneca PLC posted a loss in the second quarter as it furiously invested in its next-generation drugs while battling falling sales of its aging blockbuster Crestor, and took a restructuring charge relating to a cost-reduction program.

Source: Wall Street Journal July 28, 2016 07:41 UTC